ArrayPatch

ArrayPatch is developing a patented dissolving microneedle drug delivery platform called DerMap, effective delivery of medicines through the skin. Its lead product, ITZ-DerMap, targets nail fungal infections, with further applications in skin cancer, weight loss, diabetes and migraine.

Key highlights: 

• Winner of the InterTradeIreland All-Island Seedcorn Investor Readiness Competition 2025.
• DerMap-Breakthrough platform technology attracting strong industry interest.
• Protected by patent filings in multiple jurisdictions.
• The lead product from platform, ITZ-Dermap™, targets nail fungal infections-a disease that affects 1 in 4 people globally.
• Global nail fungal treatment market valued at $4.7bn in 2022, projected to reach $6.2bn by 2027.
• Proof of concept completed with strong preclinical data indicating commercial potential.
• ITZ-DerMap™ has potential to deliver superior patient outcomes-higher cure rates and shorter treatment times versus current treatments, and higher compliance.
• Additional DerMap applications include skin cancer, migraine, diabetes and weight loss-markets worth >$70bn.
• Enterprise Ireland HPSU company.
• More than €1.3m invested in the technology prior to spin-out from UCC.
• Raising seed round with €1.68m in equity investment committed.
• Lead investor: Lakeside Capital.
• Platform technology provides multiple exit avenues for investors.
• World class management team accumulating more than 75 years of commercial and industrial experience.